Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01966341
Other study ID # CR-13-108
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date April 2014
Est. completion date April 2016

Study information

Verified date May 2019
Source Seton Healthcare Family
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This program has been created to help patients with irritable bowel syndrome manage their symptoms and increase their functioning by using cognitive therapy skills and hypnosis.


Description:

Functional Gastrointestinal Diseases (FGID) are a family disorders that are characterized by gastrointestinal symptoms in the absence of readily identifiable organic pathology. Examples of FGID include irritable bowel syndrome, rumination syndrome, and function constipation. These disorders are classically thought to stem from dysfunction of the enteric nervous system. However, there is a growing recognition that multiple factors play a role in the genesis of FGIDs. This idea is encapsulated by the "biopsychosocial" model of disease, and is supported by a body of literature which has identified higher rates of FGID in patients with anxiety, depression, post-traumatic stress disorder, agoraphobia, and other psychosocial dysfunction.

Recurrent Abdominal Pain and Irritable Bowel Syndrome are major causes of pediatric morbidity. Over a third of children and adolescents report recurrent abdominal pain, and the overall prevalence of non-organic abdominal pain has been noted to be over 75% 1 2. A large subset of these children report symptoms that are consistent with irritable bowel syndrome. Management of these children is complex and includes medical, dietary, and behavioral interventions. Medical therapy often revolves around the use of antispasmodics, probiotics, and antidepressants. The data supporting their use, however has been mixed.

Over the last twenty years behavioral therapies such as cognitive behavioral therapy (CBT) and hypnotherapy (HT) have come to light as major treatment modalities for functional gastrointestinal disease. In a large multicenter randomized controlled trial Levy et al compared 3-session CBT to a control intervention and noted significant improvements and pain and function in children 3. Similar results have been published in multiple smaller trials 4-8. Likewise, Vlieger et al compared hypnotherapy to standard medical therapy in 53 children with irritable bowel syndrome. They found that, while both interventions resulted in improved pain scores, the hypnotherapy group demonstrated lasting clinical improvement at 1 year followup 9. Five year follow-up data has recently been published and revealed that significantly more of the hypnotherapy group remained in remission without any further intervention 10. A growing body of literature is available validating the use of hypnotherapy in irritable bowel syndrome in adults, and pain syndromes more generally 11-14.

These therapies can be viewed as complementary to one another. CBT involves a very deliberate conscious understanding of ones disease process and triggers and focuses on successful pain mitigation measures. HT recruits the imagination with utilization of therapeutic imagery to down regulate inappropriate pain responses. Our center has developed a collaborative approach, utilizing both CBT and HT for the treatment of refractory IBS. To our knowledge no work has been done assessing the efficacy of such a collaborative approach using both CBT and HT in children with functional gastrointestinal disease. We therefore propose the following randomized case-control crossover trial to assess the efficacy our combined program.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date April 2016
Est. primary completion date April 2016
Accepts healthy volunteers No
Gender All
Age group 8 Years to 18 Years
Eligibility Inclusion Criteria:

- Age 8 - 18

- Meets Rome III Criteria for Pediatric Irritable Bowel Syndrome

- Abdominal discomfort or pain associated with 2 or more of the following at least 25% of the time

- Improved with defecation

- Onset associated with a change in frequency of stool

- Onset associated with a change in form of the stool

- No evidence of inflammatory, anatomic, metabolic, or neoplastic process that explains the subject's symptoms

- Criteria fulfilled once per week for at least 2 months before diagnosis

Exclusion Criteria: Unwillingness / Inability to engage in cognitive behavioral therapy arm of study (weekly encounters with psychologist)

Study Design


Intervention

Behavioral:
CBT/ Hypnotherapy
The CBT program will consist of 7 sessions that will encompass the following skills of Symptom monitoring, Stress Management, Coping Skills, Relaxation training, Problem solving, and Cognitive Restructuring.The hypnotherapy program will be modeled after the North Carolina Standardized Hypnosis Treatment for Irritable Bowel Syndrome
Drug:
Routine Management
Treatment with use of antispasmodics,laxatives, and/or bulking agents (fiber) +/- antibiotics.

Locations

Country Name City State
United States 'Specially for Children, Dell Children's Medical Center of Central Texas Austin Texas

Sponsors (1)

Lead Sponsor Collaborator
Seton Healthcare Family

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Pain Response Inventory (PRI) The Pain Response Inventory (PRI) was developed as a multidimensional instrument to assess children's coping responses to recurrent pain 10 weeks
Other Pain Frequency Score / Pain Intensity Score (PFS/PIS) Our primary outcome measure will be the PFS/PIS. It involves an aggregate score of pain intensity and frequency 10 weeks
Other Abdominal Pain Index (API; Walker, Smith, Garber, & Van Slyke, 1997) Abdominal Pain Index comprises five items assessing the frequency, duration, and intensity of abdominal pain episodes experienced during the previous 2 weeks 10 weeks
Other Children's Somatization Inventory (CSI) The CSI assesses a variety of nonspecific somatic symptoms 10 weeks
Primary Functional Disability Inventory (FDI) The FDI is a measure of the degree to which children experience difficulty in physical and psychosocial functioning due to their physical health status. Respondents are asked to rate how much physical difficulty was perceived for a variety of everyday activities. Both child-report and parent-report versions are composed of 15 questions. 10 weeks
Secondary Pain Beliefs Questionnaire The Pain Beliefs Questionnaire is a 32-item measure assessing characteristic appraisals of pediatric abdominal pain severity (primary coping appraisals) and characteristic appraisals of ability to cope with pediatric abdominal pain (secondary coping appraisals). 10 weeks
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05795049 - Genetic Carbohydrate Maldigestion as a Model to Study Food Hypersensitivity
Withdrawn NCT02841878 - Genetic Determinism of Epithelial Barrier Defects in Irritable Bowel Syndrome N/A
Completed NCT02875847 - Effects of HMOs on Faecal Microbiota, Gastrointestinal Symptoms, Mucosal Immunity and Barrier Function in IBS Patients Phase 2
Completed NCT02842281 - Microbiome Fructan Metabolism and Symptoms in Childhood IBS N/A
Completed NCT02092402 - Fecal Microbiota Transplantation in Patients With Irritable Bowel Syndrome N/A
Completed NCT03964103 - qQ-lab Daily-IBS for Irritable Bowel Syndrome N/A
Completed NCT00401479 - A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers Phase 1
Completed NCT00421707 - Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome Phase 2
Not yet recruiting NCT06139744 - Efficacy and Safety of Dietary Supplementation of Diamine Oxidase to Improve Symptoms in Patients With IBS Phase 4
Recruiting NCT04506593 - Indiana University Gastrointestinal Motility Diagnosis Registry
Completed NCT01908465 - Peripheral Histamine 1 Receptor Blockade in IBS: Multicenter Trial Phase 4
Completed NCT01787253 - Microbe-Gut Interaction in Microscopic Colitis and Post-Infectious Irritable Bowel Syndrome (IBS)
Completed NCT00376896 - Study On The Effect Of GW876008 On Cerebral Blood Flow In Irritable Bowel Syndrome (IBS) Patients And Healthy Volunteers Phase 1
Completed NCT00904696 - Tolerability and Effectiveness of Progut in Treatment of Irritable Bowel Syndrome N/A
Recruiting NCT05453084 - Exercise and Irritable Bowel Syndrome (IBS) N/A
Completed NCT03550742 - Effect of HMOs as Nutritional Support for Normal Bowel Movements in IBS Patients N/A
Terminated NCT01887002 - Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Phase 2
Completed NCT01774695 - Physical Activity in IBS - a Long Term Follow up N/A
Completed NCT01204515 - Abdominal Symptom Phenotype Study in Children N/A
Completed NCT00067561 - Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy Phase 3